{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:16:06Z","timestamp":1785284166259,"version":"3.55.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Child Neurol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Eslicarbazepine (ESL) is a once-daily, third-generation antiseizure medication for focal-onset seizures. The primary mechanism of action is enhancing the slow inactivation of voltage-gated sodium channels. The study objective was to review real-world experience regarding retention rate, efficacy, and tolerability of eslicarbazepine, soon after it became available for children in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was performed on all patients prescribed eslicarbazepine from September 2017 to June 2020, with at least 3 years of follow-up data, at 3 Canadian tertiary care pediatric centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty patients were identified, and the mean age of eslicarbazepine initiation was 12.4 years (range 3-19 years). Most patients had drug-resistant epilepsy, trying a mean of 5.04 (range 0-14) antiseizure medications before the initiation of eslicarbazepine. Twenty-four patients (48.0%) experienced adverse effects, including dizziness (n\u2009=\u200910), drowsiness (n\u2009=\u20096), dizziness and drowsiness (n\u2009=\u20091), nausea and abdominal pain (n\u2009=\u20094), transient unsteadiness and diplopia (n\u2009=\u20091), and negative mood changes (n\u2009=\u20092). None had serious adverse effects, including rash. The retention rate of eslicarbazepine at last follow-up was 70%. Fifteen (30%) had \u226550% seizure reduction, with 2 of these patients becoming seizure free. Ten (20%) had 25% to 50% reduction, 2 (4%) had worsening of seizures, and 17 (34%) had no change in seizure frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study results support the long-term effectiveness and tolerability of eslicarbazepine in a cohort of children with predominantly drug-resistant epilepsy in a real-life setting from 3 Canadian centers with initial use after approval. Adverse effects were nonserious, infrequently leading to eslicarbazepine discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08830738241282903","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:33:10Z","timestamp":1728358390000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Initial Experience of Eslicarbazepine in Children at Three Canadian Tertiary Pediatric Care Centers"],"prefix":"10.1177","volume":"40","author":[{"given":"Yvonne","family":"Nyakeri","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Neurology, BC Children's Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology, Health Sciences Centre Children's Hospital, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nouri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology, Western University, London, ON. Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denait","family":"Haile","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology, Western University, London, ON. Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-4868","authenticated-orcid":false,"given":"Anita N.","family":"Datta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neurology, BC Children's Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"bibr1-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2015.0736"},{"key":"bibr2-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.09.003"},{"key":"bibr3-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.11.006"},{"key":"bibr4-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.10.004"},{"key":"bibr5-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1124\/pr.120.019539"},{"key":"bibr6-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1021\/jm980627g"},{"key":"bibr7-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.09.008"},{"key":"bibr8-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0197-5"},{"key":"bibr9-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.04.019"},{"key":"bibr10-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002497"},{"key":"bibr11-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.01.029"},{"key":"bibr12-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106962"},{"key":"bibr13-08830738241282903","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.909471"},{"key":"bibr14-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"bibr15-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8618-5"},{"key":"bibr16-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106653"},{"key":"bibr17-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"bibr18-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.04.040"},{"key":"bibr19-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17843"},{"key":"bibr20-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107458"},{"key":"bibr21-08830738241282903","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597.18.1.33"},{"key":"bibr22-08830738241282903","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108515"}],"container-title":["Journal of Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08830738241282903","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08830738241282903","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08830738241282903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:41:18Z","timestamp":1777495278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08830738241282903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/08830738241282903"],"URL":"https:\/\/doi.org\/10.1177\/08830738241282903","relation":{},"ISSN":["0883-0738","1708-8283"],"issn-type":[{"value":"0883-0738","type":"print"},{"value":"1708-8283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}